NasdaqGS - Nasdaq Real Time Price USD

Bicycle Therapeutics plc (BCYC)

8.05

-0.46

(-5.41%)

At close: May 21 at 4:00:01 PM EDT

8.05

0.00

(0.00%)

After hours: May 21 at 5:08:22 PM EDT

Eckert & Ziegler SE (XTER:EUZ) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ...

Despite a cyberattack setback, Eckert & Ziegler SE (XTER:EUZ) remains optimistic about its 2025 guidance, bolstered by new partnerships and improved profitability.

GuruFocus.com 6 days ago

BCYC
-5.41%
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, England & BOSTON, May 05, 2025--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on May 1, 2025, the Compensation Committee of the company’s Board of Directors granted to 13 new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 79,500 ordinary shares. These awards were made under Bicycle Therapeutics’ 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering into empl

Business Wire 16 days ago

BCYC
-5.41%
Is Bicycle Therapeutics plc (BCYC) the Best Small Cap Stock to Buy with the Biggest Upside Potential?

We recently published a list of Top 11 Small Cap Stocks to Buy with Biggest Upside Potential. In this article, we are going to take a look at where Bicycle Therapeutics plc (NASDAQ:BCYC) stands against other top small cap stocks to buy with biggest upside potential. On April 24, Jill Carey Hall, BofA Securities head […]

Insider Monkey 16 days ago

BCYC
-5.41%
Bicycle Therapeutics First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Bicycle Therapeutics ( NASDAQ:BCYC ) First Quarter 2025 Results Key Financial Results Revenue: US$9.98m (down 49% from...

Simply Wall St. 17 days ago

BCYC
-5.41%
Bicycle Therapeutics price target lowered to $15 from $40 at Barclays

Barclays lowered the firm’s price target on Bicycle Therapeutics (BCYC) to $15 from $40 and keeps an Overweight rating on the shares following the Q1 report. The firm says the company’s pipeline catalysts remain on track. “Out of an abundance of caution,” the analyst increased the stock’s discount rate, removed deeper pipeline value, and trimmed penetration, driving the target cut. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See

TipRanks 19 days ago

BCYC
-5.41%
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results

CAMBRIDGE, England & BOSTON, May 01, 2025--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported recent business progress and financial results for the first quarter ended March 31, 2025.

Business Wire 20 days ago

BCYC
-5.41%
Bicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025

CAMBRIDGE, England & BOSTON, April 29, 2025--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, announced the presentation of additional human imaging data that validate the potential of MT1-MMP, a tumor antigen overexpressed in many cancers, as a novel target for cancer treatment and demonstrate the positive properties of Bicycle® Radioconjugates (BRC®) fo

Business Wire 22 days ago

BCYC
-5.41%
Bicycle Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

CAMBRIDGE, England & BOSTON, April 01, 2025--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, at 12:45 p.m. ET.

Business Wire last month

BCYC
-5.41%
Bicycle Therapeutics Announces New Board and Key Clinical Leadership Appointments

CAMBRIDGE, England & BOSTON, March 27, 2025--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced several new governance and key clinical leadership appointments.

Business Wire last month

BCYC
-5.41%
Bicycle Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Bicycle Therapeutics ( NASDAQ:BCYC ) Full Year 2024 Results Key Financial Results Revenue: US$35.3m (up 31% from FY...

Simply Wall St. 2 months ago

BCYC
-5.41%
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

CAMBRIDGE, England & BOSTON, February 25, 2025--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate updates.

Business Wire 2 months ago

BCYC
-5.41%
Bicycle Therapeutics (BCYC): Among The Small–Cap Stocks Insiders Are Selling Recently

We recently published a list of 10 Small–Cap Stocks Insiders Are Selling Recently. In this article, we are going to take a look at where Bicycle Therapeutics plc (NASDAQ:BCYC) stands against other small–cap stocks insiders are selling recently. Why are some investors focusing on stocks with smaller market capitalizations? Among some of the reasons are […]

Insider Monkey 3 months ago

BCYC
-5.41%
Bicycle Therapeutics (NASDAQ:BCYC) shareholders have endured a 74% loss from investing in the stock three years ago

As an investor, mistakes are inevitable. But you have a problem if you face massive losses more than once in a while...

Simply Wall St. 3 months ago

BCYC
-5.41%
Bicycle Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

CAMBRIDGE, England & BOSTON, February 05, 2025--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, Feb. 12, at 10 a.m. ET.

Business Wire 3 months ago

BCYC
-5.41%
Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones

CAMBRIDGE, England & BOSTON, January 13, 2025--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously untreated (first-line) cisplatin-ineligible patients with metastatic urothelial cancer (mUC). The company also announced recent accomplishments and

Business Wire 4 months ago

BCYC
-5.41%
Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, England & BOSTON, January 09, 2025--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate at the 43rd Annual J.P. Morgan Healthcare Conference in a podium presentation on Tuesday, Jan. 14, at 5:15 p.m. PT, followed by a question-and-answer breakout session at 5:35 p.m. PT.

Business Wire 4 months ago

BCYC
-5.41%
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients

On Thursday, Bicycle Therapeutics plc (NASDAQ:BCYC) announced that it presented data showing the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in breast cancer patients with NECTIN4 gene amplification at the 2024 San Antonio Breast Conference Symposium. The company revealed topline combination data for zelenectide pevedotin plus Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in previously untreated (first-line) cisplatin-ineligible patients with metastatic urothelial ca

Benzinga 5 months ago

BCYC
-5.41%
We're Hopeful That Bicycle Therapeutics (NASDAQ:BCYC) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Simply Wall St. 5 months ago

BCYC
-5.41%
Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification

CAMBRIDGE, England & BOSTON, December 12, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the presentation of data showing the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in breast cancer patients with NECTIN4 gene amplification at the 2024 San Antonio Breast Conference Symposium (SABCS) in San Antonio, Texas. The

Business Wire 5 months ago

BCYC
-5.41%
Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts

CAMBRIDGE, England & BOSTON, December 10, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointment of three new distinguished global oncology experts to its Clinical Advisory Board (CAB) to support the advancement of the company’s clinical oncology programs.

Business Wire 5 months ago

BCYC
-5.41%

Performance Overview

Return	BCYC	MSCI WORLD (^990100-USD-STRD)
YTD	-43.03%	+3.24%
1-Year	-62.73%	+10.45%
3-Year	-53.47%	--

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Bicycle Therapeutics plc (BCYC)

Eckert & Ziegler SE (XTER:EUZ) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ...

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Is Bicycle Therapeutics plc (BCYC) the Best Small Cap Stock to Buy with the Biggest Upside Potential?

Bicycle Therapeutics First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Bicycle Therapeutics price target lowered to $15 from $40 at Barclays

Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results

Bicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025

Bicycle Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Bicycle Therapeutics Announces New Board and Key Clinical Leadership Appointments

Bicycle Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

Bicycle Therapeutics (BCYC): Among The Small–Cap Stocks Insiders Are Selling Recently

Bicycle Therapeutics (NASDAQ:BCYC) shareholders have endured a 74% loss from investing in the stock three years ago

Bicycle Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones

Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients

We're Hopeful That Bicycle Therapeutics (NASDAQ:BCYC) Will Use Its Cash Wisely

Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification

Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts

Performance Overview